PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.
The Ordinary multipeptide hair serum is used alongside treatments like minoxidil, topical finasteride, and derma rolling, with some users reporting hair thickening and vellus hair regrowth. However, experiences vary, and some users are skeptical due to the lack of solid evidence and mixed efficacy reports.
Topical finasteride as a potential alternative to oral finasteride for reducing DHT levels on the scalp with fewer side effects, and other hair loss treatments such as minoxidil.
The user reduced serum DHT by 60% using Advanced Trichology's natural DHT blocker but saw no improvement in hair loss. They are considering switching to finasteride due to its proven effectiveness in inhibiting scalp DHT.
The conversation discusses using a 5% Topical Minoxidil with 0.01% Tretinoin serum for hair loss, noting its lack of propylene glycol to avoid itchiness and greasiness. Users share experiences with different Minoxidil formulations and discuss the effectiveness and stability of Tretinoin in various forms.
Increasing the sult1a1 enzyme on the scalp may improve response to topical minoxidil. The user suggests using a baking soda solution, DMSO, and tretinoin to enhance enzyme activity and minoxidil effectiveness.
The conversation is about a user's 5-month progress using topical Minoxidil (5%) and Finasteride (0.1%) twice daily, along with derma stamping, improved Vitamin D levels, and increased protein intake for hair regrowth. The user is considering dutasteride if progress plateaus and uses a sulfate and paraben-free shampoo.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.